TVTX - Travere Therapeutics, Inc. Stock Price, Fair Value and News

5.45USD-0.29 (-5.05%)Market Closed

Market Summary

USD5.45-0.29

Market Closed

-5.05%

TVTX Stock Price

View Fullscreen

TVTX RSI Chart

TVTX Valuation

Market Cap

436.8M

Price/Earnings (Trailing)

-3.92

Price/Sales (Trailing)

3.01

EV/EBITDA

-2.3

Price/Free Cashflow

-1.56

TVTX Price/Sales (Trailing)

TVTX Profitability

EBT Margin

-258.96%

Return on Equity

-55.47%

Return on Assets

-14.12%

Free Cashflow Yield

-64.26%

TVTX Fundamentals

TVTX Revenue

Revenue (TTM)

145.2M

Rev. Growth (Yr)

53.58%

Rev. Growth (Qtr)

21.47%

TVTX Earnings

Earnings (TTM)

-111.4M

Earnings Growth (Yr)

-36.99%

Earnings Growth (Qtr)

-159.82%

Breaking Down TVTX Revenue

Last 7 days

-6.7%

Last 30 days

-27.2%

Last 90 days

-36.6%

Trailing 12 Months

-72.8%

How does TVTX drawdown profile look like?

TVTX Financial Health

Current Ratio

3.47

Debt/Equity

1.88

Debt/Cashflow

-0.74

TVTX Investor Care

Shares Dilution (1Y)

17.54%

Diluted EPS (TTM)

-1.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	116.9M	120.5M	129.5M	145.2M
2022	126.2M	120.6M	115.1M	109.5M
2021	198.0M	204.1M	221.2M	131.8M
2020	183.5M	187.3M	194.0M	198.3M
2019	165.4M	168.8M	172.4M	175.3M
2018	159.7M	162.3M	162.7M	164.2M
2017	138.2M	143.7M	150.1M	154.9M
2016	111.5M	120.8M	126.7M	133.6M
2015	45.5M	63.9M	83.5M	99.9M
2014	7.3M	14.3M	21.2M	28.2M
2013	6.8M	4.7M	2.5M	360.0K
2012	0	0	0	9.0M
2011	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Travere Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	cline christopher r.	sold	-363	6.74	-54.00	chief financial officer
Feb 01, 2024	heerma peter	sold	-35,788	8.5313	-4,195	chief commercial officer
Feb 01, 2024	dube eric m	sold	-166,435	8.70385	-19,122	chief executive officer
Feb 01, 2024	cline christopher r.	sold	-32,572	8.5313	-3,818	chief financial officer
Feb 01, 2024	calvin sandra	sold	-24,058	8.5312	-2,820	svp, chief accounting officer
Feb 01, 2024	rote william e.	sold	-41,495	8.71014	-4,764	senior vice president, r&d
Feb 01, 2024	reed elizabeth e	sold	-41,495	8.71018	-4,764	svp, gc & corporate secretary
Feb 01, 2024	inrig jula	sold	-18,546	8.5311	-2,174	chief medical officer
Jan 31, 2024	rote william e.	acquired	-	-	25,000	senior vice president, r&d
Jan 31, 2024	cline christopher r.	acquired	-	-	25,000	chief financial officer

Which funds bought or sold TVTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-23.00	146	-%
Apr 23, 2024	RICE HALL JAMES & ASSOCIATES, LLC	added	4.47	-65,723	565,914	0.03%
Apr 23, 2024	AMALGAMATED BANK	reduced	-78.12	-72,000	16,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	1,922	345,558	-%
Apr 19, 2024	Cutler Group LLC / CA	reduced	-30.00	-7,000	10,000	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-	-	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	14.36	-6,155	314,491	0.02%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	unchanged	-	-301	1,812	-%
Apr 05, 2024	GAMMA Investing LLC	new	-	231	231	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	new	-	720,245	720,245	-%

Are Funds Buying or Selling TVTX?

Are funds buying TVTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TVTX

No. of Funds

Unveiling Travere Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.83%	7,384,000	SC 13G/A
Feb 14, 2024	deep track capital, lp	9.99%	7,522,281	SC 13G/A
Feb 14, 2024	macquarie group ltd	6.31%	4,746,144	SC 13G/A
Feb 13, 2024	vanguard group inc	7.34%	5,515,143	SC 13G/A
Feb 12, 2024	janus henderson group plc	0.0%	32,180	SC 13G/A
Feb 09, 2024	morgan stanley	5.5%	4,152,446	SC 13G
Feb 07, 2024	adage capital partners gp, l.l.c.	0.67%	5e+05	SC 13G/A
Jan 25, 2024	state street corp	7.12%	5,352,345	SC 13G/A
Jan 24, 2024	blackrock inc.	10.6%	7,990,020	SC 13G/A
Oct 06, 2023	blackrock inc.	10.3%	7,702,228	SC 13G/A

Recent SEC filings of Travere Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	4	Insider Trading
Mar 27, 2024	ARS	ARS
Mar 27, 2024	DEF 14A	DEF 14A
Mar 27, 2024	DEFA14A	DEFA14A
Feb 23, 2024	8-K	Current Report
Feb 20, 2024	10-K	Annual Report
Feb 15, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Travere Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Travere Therapeutics, Inc. News

Latest updates

Travere Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	21.5%	45,059,000	37,095,000	32,196,000	30,888,000	29,339,000	28,075,000	28,634,000	23,412,000	45,814,500	68,217,000	54,617,000	47,407,000	50,983,000	51,139,000	48,430,000	47,769,000	46,688,000	44,373,000	44,707,000	39,570,000	43,771,000
Costs and Expenses	7.4%	139,292,000	129,680,000	136,147,000	128,257,000	116,041,000	110,679,000	107,160,000	95,393,000	46,445,000	99,928,000	89,932,000	94,956,000	169,533,000	70,574,000	71,541,000	62,836,000	74,855,000	78,810,000	81,236,000	77,798,000	48,756,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	62,836,000	-	78,810,000	81,236,000	77,798,000	48,756,000
S&GA Expenses	-15.2%	57,523,500	67,801,000	74,037,000	72,245,000	51,209,500	52,420,000	52,979,000	46,788,000	18,476,000	36,065,000	34,965,000	36,778,000	35,738,000	31,951,000	34,971,000	33,139,000	27,533,000	29,779,000	38,970,000	32,669,000	25,979,000
R&D Expenses	-	-	-	-	-	-	-	-	-	-	48,407,000	51,807,000	47,946,000	-	32,349,000	30,790,000	30,249,000	36,366,000	33,220,000	37,934,000	33,443,000	32,213,000
EBITDA Margin	-Infinity%	-2.26	-	-0.98	-0.95	-0.95	-1.33	-0.85	-0.73	-0.64	-0.99	-1.01	-0.98	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	5,570,000	360,000	988,000	409,000	2,486,500	1,123,000	1,316,000	1,976,000	-206,000	2,467,000	2,589,000	2,819,000	6,956,500
Income Taxes	466.7%	68,000	12,000	65,000	78,000	63,000	145,000	53,000	52,000	4,000	43,000	49,000	313,000	-471,000	23,000	65,000	-18,976,000	32,000	-523,000	69,000	401,000	-
Earnings Before Taxes	0.8%	-88,528,000	-89,229,000	-101,867,000	-96,486,000	-85,573,000	-83,918,000	-79,970,000	-81,694,000	-88,770,000	-35,596,000	-38,963,000	-53,554,000	-122,093,000	-22,526,000	-26,003,000	-18,168,000	-30,227,000	-37,013,000	-38,632,000	-40,576,000	-7,455,000
EBT Margin	10.1%	-2.59	-2.88	-1.18	-1.14	-1.13	-1.48	-1.01	-0.88	-0.79	-1.13	-1.16	-	-	-	-	-	-	-	-	-	-
Net Income	-159.8%	-90,173,000	150,735,000	-85,630,000	-86,331,000	-65,823,000	-69,656,000	-67,032,000	-75,971,000	-51,573,000	-35,639,000	-39,012,000	-53,867,000	-121,622,000	-22,549,000	-26,068,000	808,000	-30,259,000	-36,490,000	-38,701,000	-40,977,000	-7,455,000
Net Income Margin	-14.1%	-0.77	-0.67	-1.22	-1.17	-1.17	-1.41	-1.01	-0.88	-0.79	-1.13	-1.16	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-Infinity%	-70,498,000	-	-69,927,000	-81,747,000	-54,670,000	-39,538,000	-36,823,000	-55,451,000	-27,031,000	31,714,000	6,393,000	-30,969,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.3%	789	833	736	808	673	726	779	828	777	775	747	764	607	692	679	573	605	614	648	668	709
Current Assets	-10.1%	617	686	542	605	486	535	587	631	583	579	550	565	410	498	506	407	429	440	457	476	496
Cash Equivalents	-59.7%	58.00	144	71.00	161	62.00	151	180	257	166	150	83.00	148	85.00	200	237	67.00	62.00	65.00	76.00	70.00	103
Inventory	-54.7%	9.00	21.00	19.00	7.00	5.00	7.00	8.00	7.00	7.00	7.00	7.00	7.00	8.00	7.00	6.00	7.00	6.00	5.00	5.00	6.00	6.00
Net PPE	-6.5%	7.00	8.00	9.00	9.00	9.00	10.00	10.00	11.00	11.00	12.00	12.00	12.00	9.00	6.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Goodwill	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	6.3%	588	553	620	619	630	626	623	620	475	468	414	401	396	391	360	347	384	368	370	382	391
Current Liabilities	27.6%	178	139	136	131	142	131	124	119	124	113	97.00	85.00	93.00	75.00	70.00	68.00	95.00	88.00	91.00	104	105
Long Term Debt	0.1%	377	377	376	376	376	375	375	374	227	224	221	218	215	213	210	207	205	202	200	197	195
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23.00	22.00
LT Debt, Non Current	0.1%	377	377	376	376	376	375	375	374	227	224	221	218	215	213	210	207	205	202	200	197	195
Shareholder's Equity	-28.2%	201	280	116	189	43.00	101	157	208	302	307	332	363	211	301	319	226	221	246	277	286	318
Retained Earnings	-8.7%	-1,125	-1,035	-1,186	-1,100	-1,014	-948	-878	-811	-765	-714	-678	-639	-585	-464	-441	-415	-416	-386	-349	-310	-270
Additional Paid-In Capital	0.7%	1,328	1,319	1,307	1,292	1,060	1,049	1,037	1,022	1,069	1,022	1,012	1,003	798	765	759	643	637	631	626	597	590
Shares Outstanding	0.3%	75.00	75.00	75.00	75.00	64.00	64.00	63.00	63.00	60.00	59.00	61.00	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,145	-	-	-	1,539	-	-	-	879	-	-	-	1,031	-	-	-	853	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-19.2%	-70,473	-59,134	-69,297	-81,117	-54,640	-39,525	-36,806	-55,320	-26,877	32,063	6,496	-26,474	-13,870	6,735	-6,453	-29,155	-4,492	-14,121	-19,109	-20,492	-3,565
Share Based Compensation	-24.1%	8,144	10,734	11,604	13,764	9,297	8,023	12,637	8,186	7,376	6,986	7,296	7,908	7,001	5,139	5,564	5,910	5,004	4,154	5,676	6,271	4,854
Cashflow From Investing	-112.7%	-16,950	133,318	-23,553	-37,039	-36,701	10,079	-39,096	33,165	7,370	32,520	-71,807	-105,706	-125,511	-43,169	67,802	39,551	1,580	4,465	25,230	-11,412	-48,802
Cashflow From Financing	119.6%	124	-634	2,266	216,996	551	2,278	831	113,913	33,213	2,414	303	195,753	25,039	-348	108,795	-5,773	95.00	-738	-324	-1,110	525

TVTX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Total revenue	$ 145,238	$ 109,460	$ 131,836
Operating expenses:
Cost of goods sold	11,450	4,420	3,818
Research and development	244,990	227,333	201,159
Selling, general and administrative	265,542	197,520	126,284
Restructuring	11,394	0	0
Total operating expenses	533,376	429,273	331,261
Operating loss	(388,138)	(319,813)	(199,425)
Other income (expenses), net:
Interest income	21,768	6,276	1,993
Interest expense	(11,334)	(11,014)	(19,682)
Other income, net	1,594	974	231
Loss on extinguishment of debt	0	(7,578)	0
Total other income (expense), net	12,028	(11,342)	(17,458)
Loss from continuing operations before income tax provision	(376,110)	(331,155)	(216,883)
Income tax provision on continuing operations	(223)	(313)	(409)
Loss from continuing operations, net of tax	(376,333)	(331,468)	(217,292)
Income from discontinued operations, net of tax	264,934	52,986	37,201
Net loss	$ (111,399)	$ (278,482)	$ (180,091)
Basic and diluted:
Net loss from continuing operations, basic (in dollars per share)	$ (5.07)	$ (5.20)	$ (3.63)
Net loss from continuing operations, diluted (in dollars per share)	(5.07)	(5.20)	(3.63)
Net income from discontinued operations, basic (in dollars per share)	3.57	0.83	0.62
Net income from discontinued operations, diluted (in dollars per share)	3.57	0.83	0.62
Net income (loss) per common share, basic (in dollars per share)	(1.50)	(4.37)	(3.01)
Net income (loss) per common share, diluted (in dollars per share)	$ (1.50)	$ (4.37)	$ (3.01)
Weighted average common shares outstanding, basic (in shares)	74,267,418	63,758,515	59,832,287
Weighted average common shares outstanding, diluted (in shares)	74,267,418	63,758,515	59,832,287
Comprehensive loss:
Net loss	$ (111,399)	$ (278,482)	$ (180,091)
Unrealized loss on defined benefit pension plan	(374)	(368)	0
Foreign currency translation (loss) gain	(1,871)	507	1,515
Unrealized gain (loss) on marketable debt securities	3,696	(2,484)	(1,175)
Comprehensive loss	(109,948)	(280,827)	(179,751)
Net product sales
Total revenue	127,537	97,970	115,122
Operating expenses:
Cost of goods sold	8,406	4,420	3,818
License and collaboration revenue
Total revenue	17,701	11,490	16,714
Operating expenses:
Cost of goods sold	$ 3,044	$ 0	$ 0

TVTX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 58,176	$ 61,688
Marketable debt securities, at fair value	508,675	388,557
Accounts receivable, net	21,179	16,646
Inventory, net	9,410	4,523
Prepaid expenses and other current assets	19,335	12,033
Current assets of discontinued operations	0	2,990
Total current assets	616,775	486,437
Long-term inventory, net	31,494	0
Property and equipment, net	7,479	9,049
Operating lease right of use assets	18,061	21,000
Intangible assets, net	104,443	97,073
Other assets	10,661	10,684
Non-current assets of discontinued operations	0	48,342
Total assets	788,913	672,585
Current liabilities:
Accounts payable	41,675	17,290
Accrued expenses	118,991	95,742
Deferred revenue, current portion	7,096	11,976
Operating lease liabilities, current portion	4,909	4,433
Other current liabilities	5,237	5,722
Current liabilities of discontinued operations	0	7,000
Total current liabilities	177,908	142,163
Convertible debt	377,263	375,545
Deferred revenue, less current portion	1,835	10,931
Operating lease liabilities, less current portion	22,612	27,510
Other non-current liabilities	8,485	9,385
Non-current liabilities of discontinued operations	0	64,200
Total liabilities	588,103	629,734
Commitments and contingencies (See Note 11)
Stockholders' Equity:
Preferred stock $0.0001 par value; 20,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock $0.0001 par value; 200,000,000 shares authorized; 75,367,117 and 64,290,570 issued and outstanding as of December 31, 2023 and 2022, respectively	7	6
Additional paid-in capital	1,327,881	1,059,975
Accumulated deficit	(1,125,622)	(1,014,223)
Accumulated other comprehensive loss	(1,456)	(2,907)
Total stockholders' equity	200,810	42,851
Total liabilities and stockholders' equity	$ 788,913	$ 672,585

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

CEO	Dr. Eric M. Dube Ph.D.
WEBSITE	travere.com
INDUSTRY	Biotechnology
EMPLOYEES	462

Travere Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Travere Therapeutics, Inc.? What does TVTX stand for in stocks?

TVTX is the stock ticker symbol of Travere Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Travere Therapeutics, Inc. (TVTX)?

As of Tue Apr 23 2024, market cap of Travere Therapeutics, Inc. is 436.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TVTX stock?

You can check TVTX's fair value in chart for subscribers.

What is the fair value of TVTX stock?

You can check TVTX's fair value in chart for subscribers. The fair value of Travere Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Travere Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TVTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Travere Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TVTX is over valued or under valued. Whether Travere Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Travere Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TVTX.

What is Travere Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, TVTX's PE ratio (Price to Earnings) is -3.92 and Price to Sales (PS) ratio is 3.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TVTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Travere Therapeutics, Inc.'s stock?

In the past 10 years, Travere Therapeutics, Inc. has provided -0.08 (multiply by 100 for percentage) rate of return.